SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-032984
Filing Date
2023-09-26
Accepted
2023-09-26 07:04:52
Documents
16
Period of Report
2023-09-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20230922.htm   iXBRL 8-K 36421
2 EX-10.1 ex-101payoffletteravalo9x2.htm EX-10.1 58954
3 EX-99.1 ex-991avaloxdebtpayoffpres.htm EX-99.1 20049
7 avalo-logoxblk1.jpg GRAPHIC 99614
8 htflogoa.jpg GRAPHIC 13647
  Complete submission text file 0001628280-23-032984.txt   412732

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230922.xsd EX-101.SCH 1969
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230922_lab.xml EX-101.LAB 24183
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230922_pre.xml EX-101.PRE 12576
10 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230922_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 231277153
SIC: 2834 Pharmaceutical Preparations